In 2011, Alembic Pharma Ltd(APL) was de-merged from Alembic Ltd to provide more thrust to formulations and insulate this business from the vagaries of commoditised APIs.It is trading at P/E valuation of 16.7x of 9MFY20 earnings and has a good return on equity (ROE) track record last 3 Years ROE 22.2%.Hence BUY.
Download Full Report View Full Report in BrowserPlease Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...